{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:38:31Z","timestamp":1793342311327,"version":"4.5.0"},"reference-count":22,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,3,10]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Calreticulin type I and type II mutants are drivers of the disease as they induce thrombocytosis in a retroviral mouse model. Thrombopoietin receptor MPL is required for calreticulin mutants to induce an essential thrombocythemia phenotype in transplanted mice.<\/jats:p>","DOI":"10.1182\/blood-2015-11-679571","type":"journal-article","created":{"date-parts":[[2015,11,25]],"date-time":"2015-11-25T22:14:33Z","timestamp":1448489673000},"page":"1317-1324","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":277,"title":["Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis"],"prefix":"10.1182","volume":"127","author":[{"given":"Caroline","family":"Marty","sequence":"first","affiliation":[{"name":"INSERM, Unit\u00e9 Mixte de Recherche (UMR) 1170, Villejuif, France;"},{"name":"Universit\u00e9 Paris-Saclay, UMR 1170, Villejuif, France;"},{"name":"Gustave Roussy, UMR 1170, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pecquet","sequence":"additional","affiliation":[{"name":"Signal Transduction and Molecular Hematology Unit, Ludwig Institute for Cancer Research, Brussels, Belgium;"},{"name":"de Duve Institute, Universit\u00e9 Catholique de Louvain, Brussels, Belgium; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harini","family":"Nivarthi","sequence":"additional","affiliation":[{"name":"CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"El-Khoury","sequence":"additional","affiliation":[{"name":"INSERM, Unit\u00e9 Mixte de Recherche (UMR) 1170, Villejuif, France;"},{"name":"Universit\u00e9 Paris-Saclay, UMR 1170, Villejuif, France;"},{"name":"Gustave Roussy, UMR 1170, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilyas","family":"Chachoua","sequence":"additional","affiliation":[{"name":"Signal Transduction and Molecular Hematology Unit, Ludwig Institute for Cancer Research, Brussels, Belgium;"},{"name":"de Duve Institute, Universit\u00e9 Catholique de Louvain, Brussels, Belgium; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheline","family":"Tulliez","sequence":"additional","affiliation":[{"name":"INSERM, Unit\u00e9 Mixte de Recherche (UMR) 1170, Villejuif, France;"},{"name":"Universit\u00e9 Paris-Saclay, UMR 1170, Villejuif, France;"},{"name":"Gustave Roussy, UMR 1170, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Villeval","sequence":"additional","affiliation":[{"name":"INSERM, Unit\u00e9 Mixte de Recherche (UMR) 1170, Villejuif, France;"},{"name":"Universit\u00e9 Paris-Saclay, UMR 1170, Villejuif, France;"},{"name":"Gustave Roussy, UMR 1170, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Raslova","sequence":"additional","affiliation":[{"name":"INSERM, Unit\u00e9 Mixte de Recherche (UMR) 1170, Villejuif, France;"},{"name":"Universit\u00e9 Paris-Saclay, UMR 1170, Villejuif, France;"},{"name":"Gustave Roussy, UMR 1170, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kralovics","sequence":"additional","affiliation":[{"name":"CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan N.","family":"Constantinescu","sequence":"additional","affiliation":[{"name":"Signal Transduction and Molecular Hematology Unit, Ludwig Institute for Cancer Research, Brussels, Belgium;"},{"name":"de Duve Institute, Universit\u00e9 Catholique de Louvain, Brussels, Belgium; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Plo","sequence":"additional","affiliation":[{"name":"INSERM, Unit\u00e9 Mixte de Recherche (UMR) 1170, Villejuif, France;"},{"name":"Universit\u00e9 Paris-Saclay, UMR 1170, Villejuif, France;"},{"name":"Gustave Roussy, UMR 1170, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Vainchenker","sequence":"additional","affiliation":[{"name":"INSERM, Unit\u00e9 Mixte de Recherche (UMR) 1170, Villejuif, France;"},{"name":"Universit\u00e9 Paris-Saclay, UMR 1170, Villejuif, France;"},{"name":"Gustave Roussy, UMR 1170, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111902064003400_B1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"24","key":"2019111902064003400_B2","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1182\/blood-2014-03-530865","article-title":"From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.","volume":"123","author":"Cazzola","year":"2014","journal-title":"Blood"},{"issue":"25","key":"2019111902064003400_B3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111902064003400_B4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1042\/BJ20081847","article-title":"Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum.","volume":"417","author":"Michalak","year":"2009","journal-title":"Biochem J"},{"issue":"5220","key":"2019111902064003400_B5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1126\/science.7604283","article-title":"Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I.","volume":"269","author":"Migone","year":"1995","journal-title":"Science"},{"issue":"1","key":"2019111902064003400_B6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/leu.2014.270","article-title":"Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution.","volume":"29","author":"Cabagnols","year":"2015","journal-title":"Leukemia"},{"issue":"25","key":"2019111902064003400_B7","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms.","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111902064003400_B8","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1182\/blood.V90.11.4369","article-title":"High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice.","volume":"90","author":"Villeval","year":"1997","journal-title":"Blood"},{"issue":"7","key":"2019111902064003400_B9","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"17","key":"2019111902064003400_B10","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111902064003400_B11","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2019111902064003400_B12","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2009-12-259747","article-title":"JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia.","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111902064003400_B13","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2019111902064003400_B14","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2013-04-498956","article-title":"JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN\u03b1.","volume":"122","author":"Hasan","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2019111902064003400_B15","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients.","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am J Hematol"},{"key":"2019111902064003400_B16","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms [published online ahead of print October 9, 2015].","author":"Pietra","journal-title":"Leukemia"},{"issue":"6","key":"2019111902064003400_B17","doi-asserted-by":"crossref","first-page":"e1001576","DOI":"10.1371\/journal.pbio.1001576","article-title":"Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion [published correction appears in PLoS Biol. 2015;13(3):e1002092].","volume":"11","author":"Kent","year":"2013","journal-title":"PLoS Biol"},{"issue":"10","key":"2019111902064003400_B18","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"issue":"26","key":"2019111902064003400_B19","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2014-07-587238","article-title":"The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm.","volume":"124","author":"Sangkhae","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2019111902064003400_B20","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMc1400499","article-title":"JAK inhibitor in CALR-mutant myelofibrosis.","volume":"370","author":"Passamonti","year":"2014","journal-title":"N Engl J Med"},{"issue":"7092","key":"2019111902064003400_B21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nature04703","article-title":"Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells.","volume":"441","author":"Yilmaz","year":"2006","journal-title":"Nature"},{"issue":"10","key":"2019111902064003400_B22","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/10\/1317\/1391560\/1317.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/10\/1317\/1391560\/1317.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T02:06:49Z","timestamp":1574129209000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/127\/10\/1317\/34932\/Calreticulin-mutants-in-mice-induce-an"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2015-11-679571","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725963335.793514484","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,10]]}}}